StemCells (NASDAQ: STEM) reported Q4 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $28 thousand versus the consensus estimate of $30 thousand.

For earnings history and earnings-related data on StemCells (STEM) click here.